By Jill Johnston
For over 25 years, study start-ups have plagued the pharmaceutical industry. These delays keep potentially lifesaving drugs from the patients who need them and increase costs for the R&D industry.
With so much at stake, why hasn’t the problem been solved? It hasn’t been from a lack of effort, but rather from the lack of comprehensive data and analytic tools that help operational teams predict outcomes and develop risk mitigation strategies. Gaps in key performance and quality data plus a lack of optimal processes have made it difficult to access and aggregate data into a usable format to inform decisions and improve outcomes.
Today, advances in computing and analytic capabilities enable aggregation of various public and licensed data sources to provide insights that simply did not exist before. A new approach to solving start-up delays is built on this foundation of advanced data analytics and accelerates study start-up timelines by 33 percent.